Active Ownership Group Co-Founder Appointed to Gerresheimer Supervisory Board
TL;DR
Klaus Rohrig's appointment to Gerresheimer's Supervisory Board gives the Active Ownership Group direct influence over the pharmaceutical packaging company's strategic direction.
Klaus Rohrig replaces Dr. Dorothea Wenzel on Gerresheimer's Supervisory Board and Audit Committee to reflect shareholder changes, with formal election scheduled for June 2026.
This leadership transition at Gerresheimer ensures continued oversight of safe drug delivery systems that protect patient health worldwide.
Klaus Rohrig, co-founder of Active Ownership Group, now oversees Gerresheimer's pharmaceutical packaging operations serving 13,600 employees across 16 countries.
Found this article helpful?
Share it with your network and spread the knowledge!
Klaus Rohrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. This change represents a significant shift in the oversight of one of Europe's leading pharmaceutical packaging companies and demonstrates how evolving ownership patterns can directly influence corporate governance structures.
With his appointment, Klaus Rohrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG, placing him in a crucial oversight role for the company's financial reporting and internal controls. The Audit Committee position carries substantial responsibility given Gerresheimer's position as a publicly traded company listed in the MDAX on the Frankfurt Stock Exchange. Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG, expressed gratitude for Dr. Wenzel's contributions, stating she made significant contributions to the fulfillment of the committee's duties through her expertise and experience.
The timing of this appointment comes as Gerresheimer continues to expand its global footprint in the pharmaceutical packaging industry. The company operates over 40 production sites in 16 countries across Europe, America and Asia, producing locally for regional markets. Following its combination with Bormioli Pharma, the Group generated revenues of around EUR 2.4 billion in 2024 and currently employs approximately 13,600 people worldwide. More information about the company's operations and products can be found at https://www.gerresheimer.com.
Klaus Rohrig will stand for election to the Supervisory Board at the next Annual General Meeting scheduled for June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG's co-determined Supervisory Board. This broader election process suggests additional potential changes to the company's governance structure beyond the current appointment. The composition of these positions becomes increasingly important as Gerresheimer continues to develop innovative systems and solutions for the pharma, biotech and cosmetic industries, including digital solutions for therapy support and various drug delivery systems.
The company's comprehensive portfolio includes drug containment solutions such as closures and accessories, drug delivery systems, medical devices and solutions for the health industry. Their product range spans from on-body devices, syringes, pens, auto-injectors and inhalers to vials, cartridges, ampoules, tablet containers, and various types of bottles. These changes in supervisory board composition occur as the pharmaceutical packaging industry faces increasing regulatory scrutiny and demand for enhanced sustainability, areas where Gerresheimer has positioned itself as an industry leader supporting customers with comprehensive services along the value chain.
Curated from NewMediaWire
